Reuters - Video

Edition: US | UK | IN | CN | JP

video News Agency

AbbVie looks beyond Humira with Botox-maker Allergan

Tuesday, June 25, 2019 - 01:36

Drugmaker AbbVie Inc said on Tuesday it would buy Botox-maker Allergan for about $63 billion, grabbing control of the biggest name in medical aesthetics to help reduce its reliance on blockbuster arthritis treatment Humira. Fred Katayama reports.

▲ Hide Transcript

View Transcript

Drugmaker AbbVie Inc said on Tuesday it would buy Botox-maker Allergan for about $63 billion, grabbing control of the biggest name in medical aesthetics to help reduce its reliance on blockbuster arthritis treatment Humira. Fred Katayama reports.

Press CTRL+C (Windows), CMD+C (Mac), or long-press the URL below on your mobile device to copy the code

AbbVie looks beyond Humira with Botox-maker Allergan

Tuesday, June 25, 2019 - 01:36